Cardiovascular Systems to Webcast Fiscal 2013 First-Quarter Earnings Conference Call Tuesday, Oct. 30
Live Webcast at 3:45 p.m. CT (4:45 p.m. ET)
ST. PAUL, Minn.--(BUSINESS WIRE)-- Cardiovascular Systems, Inc. (CSII) (CSI) (Nasdaq: CSII) will host a live webcast of its fiscal 2013 first-quarter conference call on Tuesday, Oct. 30, 2012, at 3:45 p.m. CT (4:45 p.m. ET). David L. Martin, president and chief executive officer, and Laurence L. Betterley, chief financial officer, will discuss the companys results for its fiscal first quarter ended Sept. 30, 2012, and its financial outlook. The company will issue a post-market earnings release on Oct. 30.
To access the live webcast, go to the investor section of the companys website, www.csi360.com, on the day of the conference call and click on the webcast icon. A webcast replay will be available beginning at 5:45 p.m. CT the same day.
To participate in the conference call, dial (888) 680-0879 and enter 16468651. Please dial in at least 10 minutes prior to the call. To pre-register for the call, log on to the following website: https://www.theconferencingservice.com/prereg/key.process?key=PKEVMRFJ3. When joining the call, pre-registered participants can enter their PIN code, and other participants can press *0 to reach the operator, or wait on the line for operator assistance.
If you do not have access to the Internet and want to listen to an audio replay of the conference call, dial (888) 286-8010 and enter access number 27392087. The audio replay will be available beginning at 5:45 p.m. CT on Tuesday, Oct. 30, 2012, through 11 p.m. CT on Tuesday, Nov. 6, 2012.
About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The companys Orbital Atherectomy Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg in a few minutes of treatment time, and addresses many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. The U.S. FDA granted 510(k) clearance for the use of the Diamondback Orbital Atherectomy System in August 2007. To date, nearly 100,000 of CSIs devices have been sold to leading institutions across the United States. CSI has also commenced its ORBIT II Investigational Device Exemption clinical trial to evaluate the safety and effectiveness of its orbital technology in treating coronary arteries. The coronary system is limited by federal law to investigational use and is currently not commercially available in the United States.
For more information, visit the companys website at www.csi360.com.
Cardiovascular Systems, Inc.
Investor Relations, 651-259-2800
Padilla Speer Beardsley Inc.
Marian Briggs, 612-455-1742
Matt Sullivan, 612-455-1709
Source: Cardiovascular Systems, Inc.Copyright Business Wire 2012